Curcumin / Theracurmin
Turmeric polyphenol inhibiting NF-κB/STAT3, inducing apoptosis, curbing angio/metastasis; strong clinical signals as chemo adjunct with bioavailability focus.
Forms: Curcumin capsules (500–2000 mg, with piperine or Theracurmin)
Simple Summary
Well-studied turmeric extract that shuts down NF-κB/STAT3 inflammation, nudges tumor cells into apoptosis, and reduces VEGF/MMPs. Bioavailability is the bottleneck—formulations like Theracurmin improve exposure. Human trials show signals across several cancers and for chemo-sensitization.
Evidence at a glance
Strong — Multiple RCTs/meta-analyses for various cancers; robust adjunct data.
How it may work
Curcumin, a turmeric-derived polyphenol, inhibits NF-κB and STAT3 pathways, reducing inflammation-driven tumor growth and metastasis. It downregulates anti-apoptotic proteins (Bcl-2, Bcl-xL), upregulates pro-apoptotic Bax, and activates caspases, inducing apoptosis. Curcumin resensitizes tumor cells to platinum-based chemotherapy by inhibiting ABC transporters and DNA repair pathways. It also suppresses VEGF, MMP-2, and MMP-9, inhibiting angiogenesis, and modulates PI3K/Akt/mTOR to limit cell proliferation.
Targets & pathways
Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.
- NF-κB / STAT3↓Reduces inflammation/metastasis
- Bcl-2 / Bcl-xL↓
- Bax↑
- Apoptosis↑Caspase activation
- Chemoresistance↓ABC transporters / DNA repair inhibited
- VEGF / MMP-2/9↓Angiogenesis / invasion suppressed
- PI3K/Akt/mTOR↓Limits proliferation
Often studied / combined with
Combinations reported in the literature, not a protocol or a recommendation.
- Piperine: Bioavailability enhancement.
- Resveratrol: NF-κB/STAT3 co-inhibition.
- Cisplatin: Resistance reversal; efficacy boost.
Overlapping mechanisms
- NF-κB ↓: Avoid stacking with other strong NF-κB inhibitors without rationale.
Safety & interactions
Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.
- CYP3A4/P-gp substrates (e.g., TKIs, chemo)MonitorModerateTheoreticalMay alter levels; pharmacist review.
- AnticoagulantsMonitorMinorTheoreticalPossible bleeding risk.
- Platinum chemotherapyConsiderBeneficialTheoreticalResensitization; enhanced efficacy.
Timing
- With meals: Enhances absorption; reduces GI upset.
- Divided doses: AM/PM for steady levels.
References
Research
No published studies for Curcumin yet
New studies appear here once they’ve been reviewed. Browse all studies.
Dose: as studied, not a recommendation
Ranges seen in adjunct / practice use: 500–8000 mg (po) Divided into 2–3 doses daily. Oncology adjunct: 1000–4000 mg/day (enhanced forms like Theracurmin for better absorption); up to 8000 mg/day in trials., No Rx required. Use bioavailable forms (e.g., with piperine/Theracurmin); take with meals. Clinician oversight for oncology; monitor LFTs at high doses..
Trials studying Curcumin / Theracurmin
Loading current trials from ClinicalTrials.gov… Search ClinicalTrials.gov →
Appears in these protocol claims
Curcumin / Theracurmin is named in these protocols discussed online. Listed for transparency: being part of a protocol is not evidence that it works, and OncoForge does not endorse them.
- Joe Tippens / Fenbendazole Protocol : Fenbendazole-centered supplement stack popularized through a remission story and online groups.
- Ivermectin / Benzimidazole Protocol Claims : Aggressive online protocols combining ivermectin with fenbendazole or mebendazole.
- Jane McLelland / Metabolic Blocking Claims : Multi-pathway metabolic strategy based around starving cancer fuel routes and blocking escape pathways.